Ancrod
As of the edition of 20 October 2026, Ancrod is a drug: went quiet in 2018; acts on FGA, FGB and FGG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2018
- Kind
- Unknown
- Registered trials
- 4, 2 stopped early
- Disease areas
- Nervous system; Heart and blood vessels; Ear, nose and throat
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 3 | 1 | 0 | 2 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Neurobiological Technologies | Lead sponsor of trials | 2005 to now |
| Nordmark Arzneimittel | Lead sponsor of trials | 2013 to now |